Peter van Rooij
Papers
1
Total Citations
51
H-Index
1
About
Peter van Rooij is a leading figure in radiation oncology, with a primary focus on stereotactic body radiotherapy (SBRT) for prostate cancer. His major contributions center on the clinical implementation and validation of CyberKnife technology, demonstrating that extreme hypofractionation—delivering high-dose radiation in just a few sessions—is both feasible and well-tolerated for low- to intermediate-stage disease. His seminal 2010 paper, with 51 citations, provided early evidence that this approach achieves excellent dose conformation while minimizing toxicity, helping to shift the standard of care toward shorter, more convenient treatment regimens. Beyond this foundational work, van Rooij has been instrumental in refining treatment protocols, optimizing patient selection, and publishing long-term outcomes that confirm the durability and safety of SBRT. His research has directly influenced clinical guidelines and expanded access to non-invasive, high-precision radiotherapy. With a career dedicated to translating technological innovation into tangible patient benefits, van Rooij remains a respected authority whose work continues to shape the future of prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1